FDA Does Not Approve TKI Surufatinib for Neuroendocrine Tumors ...Middle East

Drug manufacturer Hutchmed said the FDA sent the company a complete response letter indicating that the agency requires a multiregional clinical trial before approving the drug in the US. News Alerts

Hence then, the article about fda does not approve tki surufatinib for neuroendocrine tumors was published today ( Monday 02/05/2022 - 04:42 PM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Does Not Approve TKI Surufatinib for Neuroendocrine Tumors )

Also on site :

• 30–35 terrorists on radar: Army steps up counterterror ops in J&K; intense vigil amid 'Chillai Kalan'
• Nine Years After Carrie Fisher Died, Billie Lourd Says Mom “Lives on Through Joy” With Kids, Dad Bryan Lourd
• No. 20 Virginia notches first 11-win season by beating 25th-ranked Missouri in the Gator Bowl